XOMA Corporation (XOMA)

[mbmalone]

Lobbyist(s): Pat Scannon
Agency: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Defense - Dept of (DOD)

Date Issue(s) Client Income Expenses
2009-03-31 Defense XOMA (US) LLC 0 130,000
2009-06-30 Defense XOMA (US) LLC 0 120,000
2009-09-30 Defense, Medical / Disease Research / Clinical Labs XOMA (US) LLC 0 90,000

ISSUES RELATING TO BIODEFENSE AND NATIONAL SECURITY, SPECIFICALLY FULL FUNDING FOR MEDICAL COUNTERMEASURE DEVELOPMENT VIA THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA). ISSUES REGARDING CRITICAL GOVERNMENT NEEDS FOR FLEXIBLE BIOPHARMACEUTICAL MANUFACTURING AND ADVANCED DEVELOPMENT OF MEDICAL COUNTERMEASURES AGAINST CHEMICAL, BIOLOGICAL, NUCLEAR AND RADIOLOGICAL, AND EMERGING DISEASE THREATS. ISSUES RELATING TO BIOTECH JOB CREATION AND BARDA PROGRAMS.
H.R. 1 / S. 336 "AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009," ALL PROVISIONS RELATING TO BARDA FUNDING. H.R. 1105 "OMNIBUS APPROPRIATIONS ACT, 2009," ALL PROVISIONS RELATING TO BARDA FUNDING VIA THE PUBLIC HEALTH AND SOCIAL SERVICES EMERGENCY FUND OF HHS. ISSUES REGARDING HOMELAND SECURITY PRESIDENTIAL DIRECTIVE 1, SPECIFICALLY PERTAINING TO WHITE HOUSE BIODEFENSE ORGANIZATIONAL STRUCTURE AND TO CHANGES WITHIN THE OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE. ISSUES RELATING TO BIOTERRORISM STORIES IN THE NEWS AND TO PANDEMIC INFLUENZA AND BARDA PROGRAM DETAILS. ISSUES RELATING TO BARDA FY09 PRIORITIES OVERALL.